A Comparison of Pregnancy Outcomes in Patients Undergoing Donor Egg Single Embryo Transfers With and Without Preimplantation Genetic Testing

2018 ◽  
Vol 26 (12) ◽  
pp. 1661-1665 ◽  
Author(s):  
Alexis K. Masbou ◽  
Jenna B. Friedenthal ◽  
David H. McCulloh ◽  
Caroline McCaffrey ◽  
M. Elizabeth Fino ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Pregnancy Outcomes ◽  
Implantation Rate ◽  
Live Birth Rate ◽  
Oocyte Donation ◽  
Single Embryo Transfer ◽  
Freezing Process ◽  
Preimplantation Genetic Testing ◽  
Comparison Groups ◽  
Donor Egg

Two of the many milestone developments in the field of assisted reproduction have been oocyte donation and preimplantation genetic testing for aneuploidy (PGT-A). Because it has been demonstrated that even young women produce a meaningful proportion of aneuploid embryos, screening out such abnormalities could potentially increase the efficacy of donor egg (DE) cycles. In this retrospective cohort study, we investigated the effect of PGT-A on DE cycle outcomes, including implantation rate (IR), spontaneous abortion rate (SABR), and ongoing pregnancy/live birth rate. We used fresh and frozen donor cycles not using PGT-A as comparison groups; all cases involved single embryo transfer. Data analysis revealed that PGT-A did not improve pregnancy outcome metrics in DE cycles, although there was a trend toward decreasing the SABR. There was a significant increase in IR with fresh cycles outperforming all frozen cycles. Overall, these results suggest that the benefits of performing PGT-A on embryos derived from young DEs may be limited and that there is an effect of the freezing process on pregnancy outcomes. These findings may provide useful insights into the science and practice of PGT-A across all of its applications.

scholarly journals Preimplantation genetic testing of embryos in donor egg cycles is associated with a decrease in the number of embryos transferred and an improved implantation rate

2016 ◽  
Vol 105 (2) ◽  
pp. e6-e7 ◽  
Author(s):  
Lucky Sekhon ◽  
Tanmoy Mukherjee ◽  
Rose M. Moschini ◽  
Joseph A. Lee ◽  
Christine Briton-Jones ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Implantation Rate ◽  
Preimplantation Genetic Testing ◽  
Donor Egg

scholarly journals Preimplantation genetic testing for aneuploidy in uterus transplant patients

2021 ◽  
Vol 15 ◽  
pp. 263349412110098
Author(s):  
Rhea Chattopadhyay ◽  
Elliott Richards ◽  
Valerie Libby ◽  
Rebecca Flyckt
Keyword(s):  
Genetic Testing ◽  
In Vitro Fertilization ◽  
Immunosuppressive Agents ◽  
Live Birth Rate ◽  
Preimplantation Genetic Testing ◽  
Vitro Fertilization ◽  
Uterus Transplantation ◽  
Advantages And Disadvantages ◽  
Dilation And Curettage

Uterus transplantation is an emerging treatment for uterine factor infertility. In vitro fertilization with cryopreservation of embryos prior is required before a patient can be listed for transplant. Whether or not to perform universal preimplantation genetic testing for aneuploidy should be addressed by centers considering a uterus transplant program. The advantages and disadvantages of preimplantation genetic testing for aneuploidy in this unique population are presented. The available literature is reviewed to determine the utility of preimplantation genetic testing for aneuploidy in uterus transplantation protocols. Theoretical benefits of preimplantation genetic testing for aneuploidy include decreased time to pregnancy in a population that benefits from minimization of exposure to immunosuppressive agents and decreased chance of spontaneous abortion requiring a dilation and curettage. Drawbacks include increased cost per in vitro fertilization cycle, increased number of required in vitro fertilization cycles to achieve a suitable number of embryos prior to listing for transplant, and a questionable benefit to live birth rate in younger patients. Thoughtful consideration of whether or not to use preimplantation genetic testing for aneuploidy is necessary in uterus transplant trials. Age is likely a primary factor that can be useful in determining which uterus transplant recipients benefit from preimplantation genetic testing for aneuploidy.

scholarly journals Do donor oocyte recipients benefit from preimplantation genetic testing for aneuploidy(PGT-A) to improve pregnancy outcomes?

2018 ◽  
Vol 110 (4) ◽  
pp. e72-e73
Author(s):  
N. Doyle ◽  
M. Gainty ◽  
J.O. Doyle ◽  
M. Levy ◽  
A.H. DeCherney ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Pregnancy Outcomes ◽  
Preimplantation Genetic Testing ◽  
Donor Oocyte

scholarly journals The Appropriate Time Interval Between Hysteroscopic Polypectomy and the Start of FET : A Retrospective Corchort Study

2020 ◽  
Author(s):  
Zhong-Kai Wang ◽  
Hong-Wu Qiao ◽  
She-Ling Wu ◽  
Wen Zhang ◽  
Xiao-Na Yu ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Implantation Rate ◽  
Live Birth Rate ◽  
Time Interval ◽  
Miscarriage Rate ◽  
Endometrial Polyps ◽  
Group 4 ◽  
Academic Center ◽  
Group 2 ◽  
Group 1

Abstract Objective: To investigate when is the appropriate time interval between hysteroscopic polypectomy and the start of FET cyclesDesign: Retrospective cohort study. Setting: Academic center. Patient(s): All patients diagnosed with endometrial polyps undergoing hysteroscopic polypectomy before FET.Intervention(s): Hysteroscopic polypectomy.MainOutcomeMeasure(s): Patients were divided into four groups based on the time interval between hysteroscopic polypectomy and the start of FET Demographics, baseline FET characteristics, pregnancy outcomes after FET were compared among the groups. A total of 1703 patients met inclusion criteria: 547 patients in group 1 who underwent FET after hysteroscopic polypectomy 1-3menses cycles, 389 patients in group 2 who underwent FET after hysteroscopic polypectomy 4-6 menses cycles, 421 patients in group 3 who underwent FET after hysteroscopic polypectomy 7-12menses cycles, and 373 patients in group 4 who underwent FET after hysteroscopic polypectomy more than 12 menses cycles, whats more the group 1 were divided into 3 groups depend on the time interval between hysteroscopic polypectomy and the start of FET. The FET outcomes were compared.Result(s): There were no differences in the mean number of embryos transferred. The overall pregnancy outcomes were similar for groups 1, 2, 3,and 4: implantation rate (38%, 38.2%, 39.5%and 36.8, respectively), clinical pregnancy rate (51.9%, 48%, 53.2and 50%), spontaneous miscarriage rate (8.4%,8.4%, 12.2and 8.9%), and live birth rate (42.4%. 40.4%, 42.8% and 40.9%). Conclusion(s): IVF outcomes seem to be unrelated to the time interval between the hysteroscopic polyp resection and the initiation of the FET; The abortion rates may be lower if the treatment is started in the first few months post operatively.

scholarly journals Case Report: Preimplantation Genetic Testing and Pregnancy Outcomes in Women With Alport Syndrome

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei-Hui Shi ◽  
Mu-Jin Ye ◽  
Song-Chang Chen ◽  
Jun-Yu Zhang ◽  
Yi-Yao Chen ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Kidney Disease ◽  
Pregnancy Outcomes ◽  
Alport Syndrome ◽  
Kidney Diseases ◽  
High Rate ◽  
Singleton Pregnancy ◽  
Fetal Outcomes ◽  
Preimplantation Genetic Testing ◽  
Monogenic Diseases

BackgroundAlport syndrome, a monogenic kidney disease, is characterized by progressive hemorrhagic nephritis, sensorineural hearing loss, and ocular abnormalities. Mutations in COL4A5 at Xq22 accounts for 80–85% of X-linked Alport syndrome patients. Three couples were referred to our reproductive genetics clinic for prenatal or preconception counseling.MethodsPrenatal diagnoses were performed by amplifying targeted regions of COL4A5. Targeted next-generation sequencing (NGS)-based haplotype analysis or karyomapping was performed in two patients. Pregnancy outcomes in the three patients were collected and analyzed. Published Alport syndrome cases were searched in Pubmed and Embase.ResultsPrenatal diagnoses in two cases showed one fetus harbored the same pathogenic mutation as the proband and the other was healthy. The couple with an affected fetus and the patient with a family history of Alport syndrome chose to take the preimplantation genetic testing (PGT) procedure. One unaffected embryo was transferred to the uterus, and a singleton pregnancy was achieved, respectively. Two patients presented non-nephrotic range proteinuria (<3 g/24 h) during pregnancy and the three cases all delivered at full-term. However, published Alport cases with chronic kidney disease or proteinuria during pregnancy were came with a high rate (75%) of adverse maternal and fetal outcomes.ConclusionThe PGT procedure performed in this study was proven to be practicable and might be expanded to be applied in other monogenic diseases. Moderate or severe renal impairments in Alport syndrome were strongly associated with adverse maternal and fetal outcomes, and baseline proteinuria was a potential predictor for pregnancy outcomes of Alport syndrome as other kidney diseases.

scholarly journals Different Strategies of Preimplantation Genetic Testing for Aneuploidies in Women of Advanced Maternal Age: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (17) ◽  
pp. 3895
Author(s):  
Wei-Hui Shi ◽  
Zi-Ru Jiang ◽  
Zhi-Yang Zhou ◽  
Mu-Jin Ye ◽  
Ning-Xin Qin ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Live Birth ◽  
Maternal Age ◽  
Birth Rate ◽  
Live Birth Rate ◽  
Advanced Maternal Age ◽  
Controlled Trials ◽  
Preimplantation Genetic Testing ◽  
Randomized Controlled ◽  
Blastocyst Biopsy

Background: Preimplantation genetic testing for aneuploidies (PGT-A) is widely used in women of advanced maternal age (AMA). However, the effectiveness remains controversial. Method: We conducted a comprehensive literature review comparing outcomes of IVF with or without PGT-A in women of AMA in PubMed, Embase, and the Cochrane Central Register of Controlled Trials in January 2021. All included trials met the criteria that constituted a randomized controlled trial for PGT-A involving women of AMA (≥35 years). Reviews, conference abstracts, and observational studies were excluded. The primary outcome was the live birth rate in included random control trials (RCTs). Results: Nine randomized controlled trials met our inclusion criteria. For techniques of genetic analysis, three trials (270 events) performed with comprehensive chromosomal screening showed that the live birth rate was significantly higher in the women randomized to IVF/ICSI with PGT-A (RR = 1.30, 95% CI 1.03–1.65), which was not observed in six trials used with FISH as well as all nine trials. For different stages of embryo biopsy, only the subgroup of blastocyst biopsy showed a higher live birth rate in women with PGT-A (RR = 1.36, 95% CI 1.04–1.79). Conclusion: The application of comprehensive chromosome screening showed a beneficial effect of PGT-A in women of AMA compared with FISH. Moreover, blastocyst biopsy seemed to be associated with a better outcome than polar body biopsy and cleavage-stage biopsy.

P–602 Pregnancy outcomes of progestin primed ovarian stimulation protocol, GnRH antagonist protocol and GnRH agonist protocol for young patients undergoing PGT-M

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Y Li ◽  
W Zhao ◽  
X Liang
Keyword(s):  
Genetic Testing ◽  
Gnrh Agonist ◽  
Pregnancy Outcomes ◽  
Ovarian Stimulation ◽  
Gnrh Antagonist ◽  
Young Patients ◽  
Stimulation Protocol ◽  
Preimplantation Genetic Testing ◽  
Gnrh Antagonist Protocol ◽  
Antagonist Protocol

Abstract Study question To investigate the pregnancy outcomes of progestin primed ovarian stimulation protocol, GnRH antagonist protocol and GnRH agonist protocol for young patients undergoing preimplantation genetic testing for monogenic gene diseases. Summary answer PPOS protocol could reduce the normal chromosome formation and further development potential of embryos, suggesting that the PPOS protocol should be used cautiously. What is known already GnRH antagonist protocol (GnRHant) and GnRH agonist protocol (GnRHa) have been used in clinic for many years as routine regimens, and their ovarian stimulation effects and pregnancy outcomes have been confirmed by a large number of literatures. As a new protocol in recent years, the reports of pregnancy outcomes of progestin primed ovarian stimulation protocol (PPOS) are inconsistent. Study design, size, duration This retrospective cohort study was performed in a reproduction center from a tertiary hospital between September 2018 and November 2020 which included 147 young patients (<35 year old) undergoing preimplantation genetic testing for monogenic gene diseases (PGT-M) after stimulated by progestin primed ovarian stimulation protocol (n = 44), GnRH antagonist protocol (n = 60) or GnRH agonist protocol (n = 43). Participants/materials, setting, methods This study included 147 young patients (<35 year old) undergoing preimplantation genetic testing for monogenic gene diseases (PGT-M) after stimulated by progestin primed ovarian stimulation protocol (PPOS, n = 44), GnRH antagonist protocol (GnRHant, n = 60) or GnRH agonist protocol (GnRHa, n = 43). The primary outcomes were normal karyotype embryo rate and live birth rate. The embryological and clinical outcomes were measured. Main results and the role of chance Basic characteristics such as infertility duration, age, and body mass index (BMI) were comparable in study groups. No significant difference was found in the number oocytes retrieved or viable embryos between the groups. Normal karyotype embryo rate of PPOS protocol was significantly lower than GnRHant and GnRHa protocol (57.6% for PPOS vs 76.0% for GnRHant vs 67.3% for GnRHa). No significant difference were found in chemical pregnancy rate (77.3% for PPOS vs 73.3% for GnRHant vs 74.4% for GnRHa) or clinical pregnancy rate (69.8% for PPOS vs 71.7% for GnRHant vs 72.5% for GnRHa). While live birth rate of PPOS protocol was significantly lower than GnRHant and GnRHa protocol ( 45.5% for PPOS vs 58.3% for GnRHant vs 72.2% for GnRHa). Limitations, reasons for caution This is a preliminary study which needs to be further confirmed by large-scale clinical studies. Wider implications of the findings: Although this is a preliminary study which needs to be further confirmed by large-scale clinical studies, the current results suggest that the application of PPOS should be cautious. Trial registration number -

Sign in / Sign up

Export Citation Format

Share Document